Pheast Therapeutics has begun a phase 1 trial for PHST001, targeting CD24 in advanced solid tumors, to evaluate safety and determine the phase 2 dose. PHST001 has shown promising preclinical results, ...

In 2009, OncoImmune’s founders identified a signal transducer molecule, CD24, which suppresses inflammation by binding to a pattern recognition receptor called Siglec10. They further determined ...